[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 215
1. Anderson WF, Devesa SS: In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer; 2005 Oct 15;104(8):1733-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
  • BACKGROUND: In situ breast carcinoma is not so well characterized for men as for women.
  • METHODS: Therefore, the authors of the current study compared male and female in situ and invasive breast carcinomas in the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute to document these patterns.
  • RESULTS: In situ breast carcinomas composed 9.4% of all male (n = 280 of 2984) and 11.9% of all female breast carcinomas (n = 53,928 of 454,405) during the years 1973-2001.
  • In situ rates rose 123% for men and 555% for women over this time period; whereas distant disease rates fell for both genders.
  • Median ages at diagnosis were 62 years for in situ and 68 years for invasive breast carcinoma among men, compared with 58 years for in situ and 62 years for invasive breast carcinoma among women.
  • Papillary in situ and invasive architectural types were more common among men than women.
  • Breast cancer-specific survival was similar among men and women, whereas overall survival was worse for men than women.
  • CONCLUSION: In situ male breast carcinoma is a rare disease, occurring at older ages and with different architectural types than its more common female counterpart.
  • Gender-specific histopathologic differences probably reflect anatomic differences among the normal female and vestigial male breast.
  • Rising in situ male breast carcinoma incidence rates over the past three decades suggest earlier detection over time, irrespective of mammography, because men do not participate in routine screening mammography.
  • [MeSH-major] Breast Neoplasms, Male / epidemiology. SEER Program / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / epidemiology. Risk Factors. Survival Rate. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16138363.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


2. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP; 2006;7(3):283-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
  • CONTEXT: HER2/neu overexpression is observed in many cancers including pancreatic ductal adenocarcinoma.
  • Immunohistochemistry (clone TAB 250) and chromogenic (HER2/neu amplification Spot Light kit) in situ hybridization protocols were performed.
  • In contrast to breast cancer, protein overexpression does not predict this specific gene deregulation mechanism.
  • Furthermore, evaluation of HER2/neu protein expression based on digital image analysis and not only on conventional eye microscopy improves the accuracy and reliability of immunohistochemical estimation, although that does not demonstrate clinical significance and prognostic value in pancreatic ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Ductal, Breast / metabolism. Gene Amplification. Genes, erbB-2. Pancreatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Aged. Aneuploidy. Chromosomes, Human, Pair 17. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry / methods. In Situ Hybridization. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reproducibility of Results. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685109.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


3. Fujiwara A, Shibata E, Terashima H, Shishido A, Nishiki J, Yoshida K, Miyauchi K, Madachi A, Matsuura N: Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. Breast Cancer; 2006;13(3):272-8
Hazardous Substances Data Bank. GELATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors.
  • BACKGROUND: Fine-needle aspiration (FNA) biopsy of breast tumors is a reliable diagnostic method for identifying breast carcinoma.
  • To improve the cytological diagnosis of breast tumors, we investigated the expression of active matrix metalloproteinase-2 (MMP-2), as detected by film in situ zymography (FIZ).
  • METHODS: We evaluated 34 fresh breast tumors, 25 paraffin-embedded breast tissue specimens, and a human cancer cell line (HT1080).
  • Frozen sections and aspiration cytology samples of breast cancer were incubated on gelatin-coated films for the detection of active MMP-2.
  • RESULTS: Immunohistochemistry showed that MMP-2 was expressed in cancer cells and stromal cells, but not in most benign breast lesions.
  • Gelatinolytic activity was also detected by FIZ analysis of aspiration cytology samples and frozen sections from the breast cancers, and there was a significant correlation between this gelatinolytic activity and the detection of MMP-2 expression by immunocytochemistry.
  • CONCLUSIONS: The present study demonstrated that measurement of gelatinolytic activity by FIZ analysis of aspiration cytology samples may be useful for improving the cytological diagnosis of breast tumors.
  • [MeSH-major] Breast Neoplasms / enzymology. Gelatin / metabolism. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / enzymology. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / enzymology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929121.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / gelatin film; 9000-70-8 / Gelatin; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


Advertisement
4. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • METHODS AND RESULTS: Forty-four patients [18 BO, 13 BO with dysplasia (five low-grade dysplasia, eight high-grade dysplasia) and 13 ADC in BO] were evaluated by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Chromosomes, Human, Pair 17 / genetics. Diagnosis, Differential. Female. Gene Amplification. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


5. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • Histologically, the excised lesion showed features of tubulopapillary apocrine hidradenoma, with an area showing features of carcinoma in situ.
  • The lesion also had papillary and cribriform growth patterns, reminiscent of breast lesions.
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Layfield LJ, Lewis C: In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Anal Quant Cytol Histol; 2007 Aug;29(4):239-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status.
  • OBJECTIVE: To compare the relationship between Her-2/neu in the invasive and in situ components of carcinoma.
  • STUDY DESIGN: Using immunohistochemistry, this study compares the Her-2/neu status in the in situ and invasive components of 200 cases of ductal carcinoma of the breast.
  • RESULTS: Twenty-five cases (12.5%) demonstrated a difference of 2 or more grades between the in situ and invasive components.
  • The in situ component always showed higher expression of Her-2/neu than did the invasive component when protein expression was discordant.
  • Comedo carcinoma was the in situ component in 12 of the 25 discordances in Her-2/neu expression.
  • CONCLUSION: Significant heterogeneity exists between Her-2/neu expression in the in situ component and invasive components of adenocarcinoma of the breast.
  • When discordance exists, the in situ component shows higher levels of expression.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879632.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


7. Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, Tubbs RR: Metallographic in situ hybridization. Hum Pathol; 2007 Aug;38(8):1145-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallographic in situ hybridization.
  • Metallographic methods, in which a target is visualized using a probe or antibody that deposits metal selectively at its binding site, offers many advantages for bright-field in situ hybridization (ISH) detection as well as for other labeling and detection methods.
  • Enzyme metallography, a novel procedure in which an enzymatic probe is used to deposit metal directly from solution, has been used to develop bright-field ISH methods for HER2 gene determination in breast cancer and other biopsy specimens.
  • [MeSH-major] Gold Colloid / chemistry. In Situ Hybridization / methods. Nucleic Acids / chemistry. Silver Compounds / chemistry. Silver Staining / methods
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Breast Neoplasms / chemistry. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Enzymes / chemistry. Female. Humans. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics

  • Hazardous Substances Data Bank. SILVER COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640553.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R43CA111182-01; United States / NCI NIH HHS / CA / 5R42CA83618-03; United States / NIGMS NIH HHS / GM / 5R44 GM064257-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes; 0 / Gold Colloid; 0 / Nucleic Acids; 0 / Silver Compounds; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 125
  •  go-up   go-down


8. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA, Banerjee SK: CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res; 2008 Sep 15;68(18):7606-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells.
  • Although previous in vitro studies predicted that CCN5/WISP-2 may act as an anti-invasive gene in breast cancer, the distribution pattern of CCN5 in breast cancer samples is conflicting.
  • Thus, we systematically investigated the CCN5 expression profile in noninvasive and invasive breast tumor samples and its functional relevance in breast cancer progression.
  • The studies showed that CCN5 expression is biphasic, such that in normal samples CCN5 expression is undetectable, whereas its expression is markedly increased in noninvasive breast lesions, including atypical ductal hyperplasia and ductal carcinoma in situ.
  • Therefore, our data suggest a protective function of CCN5 in noninvasive breast tumor cells.
  • This hypothesis was further supported by our in vitro studies illuminating that CCN5 is a negative regulator of migration and invasion of breast cancer cells, and these events could be regulated by CCN5 through the modulation of the expression of genes essential for an invasive front.
  • Collectively, these studies suggest that the protective effect of CCN5 in breast cancer progression may have important therapeutic implications.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Intercellular Signaling Peptides and Proteins / biosynthesis. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794149.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 P20 RR15563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Cadherins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP2 protein, human; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


9. Shah SS, Adelson M, Mazur MT: Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases. Int J Gynecol Pathol; 2008 Jul;27(3):453-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases.
  • Adenocarcinoma in situ rarely occurs in vulvar papillary hidradenoma.
  • We encountered 2 cases of adenocarcinoma in situ arising in a papillary hidradenoma of the vulva.
  • On microscopic examination, the tumors showed focal features of benign hidradenoma at the periphery with transitions into areas of increasing cytologic atypia that fulfilled criteria for adenocarcinoma in situ similar to that seen in the breast.
  • There was no evidence of benign ectopic breast tissue within or adjacent to the neoplasms.
  • The fact that these tumors displayed morphologic and immunohistochemical features that resembled ductal carcinoma in situ of the breast demonstrates the close homology between papillary hidradenoma and breast epithelium.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Carcinoma in Situ / pathology. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580327.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sahoo S, Recant WM: Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast. Breast J; 2005 Mar-Apr;11(2):140-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
  • Columnar cell alteration in the breast encompasses a spectrum of pathologic changes ranging from simple columnar cell change to more complex columnar cell hyperplasia with and without atypia to in situ carcinoma, often with a micropapillary architecture.
  • For reasons that remain unclear, the columnar cell lesions are associated with tubular carcinomas and lobular carcinoma in situ.
  • Therefore it is important to be familiar with the spectrum of changes and the associated lesions, especially in breast core biopsies for further management.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Breast / pathology. Calcinosis / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730461.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol; 2005 Sep;29(9):1221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
  • Breast carcinomas with amplification of HER2 on chromosome 17 are associated with HER2 protein overexpression, adversely affecting prognosis and predicting response to Herceptin therapy.
  • This impact was investigated in breast carcinomas identified by fluorescence in situ hybridization (FISH) to have a gain of chromosome 17 (CEP17+; n = 56), using a dual probe assay, which detects HER2 gene copy number and enumerates chromosome 17 (HER2/CEP17; Vysis).
  • A subgroup was evaluated by isotopic in situ hybridization for HER2 mRNA expression.
  • Isotopic in situ hybridization for HER2 mRNA performed on 26 CEP17+ cases (16 IHC 0-1+, 10 IHC 2+ or 3+) showed no increased HER2 mRNA expression (normalized to beta-actin mRNA).
  • These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17 / genetics. Genes, erbB-2 / physiology
  • [MeSH-minor] Female. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096413.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


12. Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP: Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol; 2009 Nov;33(11):1646-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
  • Low-grade precursor lesions, such flat epithelial atypia (FEA), low-grade ductal carcinoma in situ (lg-DCIS), and lobular neoplasia (LN) often coexist with invasive tubular carcinomas (TCs) of the breast.
  • Our data indicate, that in the majority of cases lg-DCIS and FEA are directly related to tubular breast cancer with a possible precursor role.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675453.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


13. Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ: The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol; 2006 Jun;32(5):502-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
  • AIM: To report the incidence and predictive value of positive axillary nodes in ductal carcinoma in situ (DCIS) and T1a carcinoma of the breast.
  • All consecutive patients with primary breast cancer that were treated between 1989 and 1998 and who had undergone axillary dissection were selected.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / secondary. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Axilla. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Node Excision. Lymph Nodes / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Retrospective Studies. Sentinel Lymph Node Biopsy. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569492.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16119 Background: Id1, involved in cell differentiation, proliferation, tumor angiogenesis and metastasis, has recently showed to mediate lung MTS from breast cancer (PNAS 2007).
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • We also observed Id1 exp. in tumor in situ areas near the invasive carcinoma in 16 out of 20 pts expressing Id1 in the primary tumor.
  • Id1 exp. in tumor in situ areas suggests Id1 as an initial factor in the BCa carcinogenic process and in the case of being confirmed Id1 could represent a target in BCa prophylaxis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer.
  • : e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type.
  • RESULTS: A pathogenic mutation located on exon 7 of the CDH1 gene was identified in a female patient diagnosed with bilateral breast cancer at the age of 36.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.
  • She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome.
  • The nonsense mutation found was probably maternally inherited, since the maternal grandmother was diagnosed with breast cancer at the age of 38.
  • CONCLUSIONS: The selection process of patients for genetic testing for the HDGC syndrome is not quite clear at the moment, as it is apparent that more types of breast cancer and not only lobular, can be associated with the syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • CASE: A 45-year-old woman who received radiotherapy for ductal carcinoma in situ (DCIS) 5 years previously had a local recurrence a year earlier and recent development of bilateral small pulmonary nodules.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • The original breast tumor was typical of cribriform DCIS.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152281.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gu M, Ghafari S, Zhao M: Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol; 2005 Sep-Oct;49(5):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
  • OBJECTIVE: To assess the usefulness of fluorescence in situ hybridization (FISH) for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy (FNAB) specimens.
  • RESULTS: FISH was performed on 41 surgical specimens of breast carcinoma.
  • Thirteen patients had prior FNABs that were positive for adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Gene Amplification / genetics. Genes, erbB-2 / genetics. In Situ Hybridization, Fluorescence / methods. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334021.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


18. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ: Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology; 2006 Feb;48(3):258-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
  • AIMS: Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) are both commonly used assays for evaluation of HER-2/neu status in breast cancer.
  • METHODS AND RESULTS: Two hundred and forty-seven breast cancer cases were studied.
  • [MeSH-major] Breast Neoplasms / chemistry. Image Processing, Computer-Assisted / methods. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / genetics. Carcinoma, Medullary / chemistry. Carcinoma, Medullary / genetics. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430472.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


19. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR: The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol; 2005 Apr;36(4):348-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
  • Clinical and in vitro evidence supports the concept that human epidermal growth factor receptor-2 ( HER2 ) gene amplification prediction of response to anthracycline-based chemotherapy in breast cancer is not a direct effect of HER2 overexpression, but the result of coamplification of topoisomerase II-alpha ( TOP2A ).
  • We investigated the relationship of TOP2A to HER2 genomic alterations by fluorescence in situ hybridization (FISH) and the correlations with polysomic states for chromosome 17 (CEP17).
  • One hundred thirty-eight cases of breast cancer HER2 gene amplified by 2-color FISH ( HER2 /CEP17) were reevaluated with a 3-color probe set ( HER2 /CEP17/ TOP2A ) to investigate the frequency of coamplification and deletion of TOP2A .
  • The current study demonstrates the complex interrelationship between the HER2 and TOP2A genes in breast cancer.
  • The clinical implications of TOP2A amplification and deletion in breast cancer need to be further defined.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Genes, erbB-2
  • [MeSH-minor] Aneuploidy. Chromosome Deletion. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Middle Aged


20. Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d'Arcy JA, Collins DJ, Padhani AR: Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology; 2010 Dec;257(3):643-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
  • PURPOSE: To investigate the histopathologic and dynamic magnetic resonance (MR) imaging correlates of intrinsic susceptibility-weighted (ISW) MR imaging in patients with primary human breast adenocarcinoma and to assess the relationship between baseline transverse relaxation rate (R2*) and T2* relaxivity change (ΔR2*) and the response to neoadjuvant chemotherapy (NAC).
  • Between September 2001 and January 2008, 83 women (median age, 46 years; age range, 26-72 years) with breast cancer were recruited to undergo dynamic contrast medium-enhanced (DCE), dynamic susceptibility contrast-enhanced (DSC), and ISW MR imaging before and after two cycles of NAC.
  • Baseline adenocarcinoma R2* (n = 31) and ΔR2* (n = 27) were correlated with final pathologic response.
  • Baseline R2* values were lower in tumors than in normal breast tissue (31.8 sec(-1) vs 36.2 sec(-1), P = .017) but not after NAC.
  • CONCLUSION: R2* is influenced by blood volume in untreated breast adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Contrast Media. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Image Interpretation, Computer-Assisted. In Situ Hybridization, Fluorescence. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Neoplasm, Residual / pathology. Prospective Studies. ROC Curve. Statistics, Nonparametric. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010
  • (PMID = 20858850.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, Moore HC, Andresen S, Crowe JP: Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol; 2007 Dec;16(4):207-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
  • The demand for both reflexed and primary fluorescence in-situ hybridization (FISH) testing in the clinical setting is increasing.
  • We report our experience with primary FISH testing in 742 consecutive cases of breast cancer, in the calendar year 2006.
  • Eighty percent (595/742) of the breast cancer cases were not amplified for HER2 (HER2/CEP17=0.8-1.9), whereas 19% (142/742) of cases were HER2 amplified (HER2/CEP17>or=2.0).
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043283.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


22. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest; 2008 Apr-May;26(3):222-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative).
  • Immunoexpressions of LIF, OSM, LIFRbeta and OSMRbeta were studied in benign breast lesion, in situ and infiltrating tumors by Western blot and immunohistochemistry.
  • Percentages of positive samples to OSM, LIF and OSMRbeta were higher in in situ carcinoma than in benign diseases and even higher in infiltrating tumors. gp130-positive samples was higher in infiltrating tumor than in benign diseases.
  • In conclusions, development of breast tumor increases the expression of OSM, LIF, OSMRbeta, LIFRbeta and gp130, and this expression may be associated with the malignancy.
  • IL-6 family exert their action through transducer receptor gp130, and gp130 expression increase with malignance, it might be a crucial point in the development of infiltrative adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Leukemia Inhibitory Factor / biosynthesis. Oncostatin M / biosynthesis. Receptors, OSM-LIF / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317962.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / OSM protein, human; 0 / Receptors, OSM-LIF; 106956-32-5 / Oncostatin M; 133483-10-0 / Cytokine Receptor gp130
  •  go-up   go-down


23. Egervari K, Szollosi Z, Nemes Z: Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol; 2008;29(1):18-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study.
  • Trastuzumab is capable of improving prognosis of HER2-positive breast cancer, but for the success of treatment appropriate HER2 testing is essential.
  • Our aim was to determine the value of immunohistochemical (IHC) screening prior to fluorescence in situ hybridization (FISH).
  • We assessed five conventional IHC assays (NCL-CB11, Pathway CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, combined with FISH on 199 invasive breast cancer cases.
  • [MeSH-major] Adenocarcinoma, Mucinous / immunology. Antibodies / immunology. Breast Neoplasms / immunology. Carcinoma, Ductal, Breast / immunology. Carcinoma, Lobular / immunology. Receptor, ErbB-2 / immunology
  • [MeSH-minor] Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18497545.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


24. Sauer T, Beraki K, Noren T, Garred O, Naess O: EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. Diagn Cytopathol; 2005 Oct;33(4):228-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization.
  • Most studies have shown epidermal growth factor receptor (EGFR) overexpression to be associated with poor prognostic factors in breast carcinomas.
  • The aim of our study was to investigate the heterogeneity of the EGFR gene copy number in breast carcinomas.
  • The material consisted of air-dried smears from 29 breast carcinomas and 3 breast cancer cell lines (MCF-7, SKBR3, and T47D).
  • Chromogenic in situ hybridization (CISH) was done using chromogenic detection.
  • There was no relationship between IHC protein expression of EGFR and EGFR gene copy number or EGFR gene/CEP7 ratio.In conclusion, most breast carcinomas had a balanced EGFR gene/CEP7 copy number with a mean ratio of 1.04.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Gene Dosage. In Situ Hybridization / methods. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16138375.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogenic Compounds; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, Acquafondata M, Pflug BR: Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol; 2006 Apr;37(4):401-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma.
  • Studies show that genes associated with an increase in protein expression, such as HER2/neu in breast cancer, are associated with an increase in gene copy number as well as an increase in transcription.
  • Using immunohistochemistry and fluorescence in situ hybridization analysis in paraffin-embedded tissue microarrays, we observed gene copy gain in 24% of all prostate adenocarcinoma specimens examined with concurrent increased FASN protein expression.
  • [MeSH-major] Adenocarcinoma / genetics. Fatty Acid Synthases / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Neoplasm Staging. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564913.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA095239
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


26. Chen CH, Rowlands C, Sengupta SK, George RL, Parulekar W, Thain K, O'Malley F, Isotalo PA: Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ. Breast J; 2009 Jul-Aug;15(4):409-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ.
  • We describe a primary invasive adenocarcinoma of the nipple with extensive basaloid features that was also associated with squamous cell carcinoma (SCC) in situ and an aggressive behavior.
  • A 69-year-old woman without a history of breast neoplasia presented with right nipple pain.
  • Biopsy of the nipple revealed SCC in situ.
  • SCC in situ was present in the overlying epidermis.
  • The differential diagnosis included a primary basaloid adenocarcinoma of the nipple, basal cell carcinoma of the nipple, neuroendocrine carcinoma, melanoma, basaloid variant of adenoid cystic carcinoma and metastatic disease.
  • Immunohistochemical profile of this tumor supported a primary basaloid adenocarcinoma of the nipple.
  • Although the initial sentinel lymph node biopsy was negative, within a year of diagnosis, the patient developed ipsilateral axillary node and pulmonary metastases.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Nipples / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601946.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Hsu YL, Uen YH, Chen Y, Liang HL, Kuo PL: Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis. J Agric Food Chem; 2009 Sep 23;57(18):8688-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis.
  • This study is the first to investigate the anticancer effect of tricetin in human breast adenocarcinoma MCF-7 cells.
  • These findings suggest that tricetin may be a promising chemopreventive agent against human breast cancer.
  • [MeSH-major] Apoptosis / drug effects. Breast Neoplasms / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Chromones / pharmacology
  • [MeSH-minor] Adenocarcinoma / pathology. Anticarcinogenic Agents. Caspase 9 / metabolism. Caspase Inhibitors. Cell Line, Tumor. G2 Phase / drug effects. Humans. In Situ Nick-End Labeling

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705844.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Caspase Inhibitors; 0 / Chromones; 520-31-0 / tricetin; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


28. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst; 2005 Jan 19;97(2):142-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
  • BACKGROUND: The incidence of esophageal adenocarcinoma is rising dramatically.
  • METHODS: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results database to extract information on incidence, stage distribution, and disease-specific mortality for esophageal adenocarcinoma as well as information on related cancers.
  • RESULTS: From 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from 4 to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.
  • The only location with increased incidence is the lower third of the esophagus-the site where adenocarcinoma typically arises.
  • Because there has been little change in the proportion of patients found with in situ or localized disease at diagnosis since 1975 (from 25% to 31%) and because esophageal adenocarcinoma mortality has increased more than sevenfold (from 2 to 15 deaths per million), overdiagnosis can be excluded as an explanation for the rise in incidence.
  • CONCLUSION: The rising incidence of esophageal adenocarcinoma represents a real increase in disease burden.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Classification / methods. Confounding Factors (Epidemiology). Cost of Illness. Cross-Sectional Studies. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. SEER Program. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jul 6;97(13):1013-4; author reply 1014 [15998956.001]
  • (PMID = 15657344.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


29. Gadre SA, Perkins GH, Sahin AA, Sneige N, Deavers MT, Middleton LP: Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology; 2008 Nov;53(5):545-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion.
  • AIMS: Ductal carcinoma in situ (DCIS) associated with invasive mucinous carcinoma (IMC) has not been well characterized.
  • The aim was to characterize mucinous DCIS (mDCIS) of the breast and to describe, to our knowledge for the first time, neovascularization in mucin.
  • Anderson Cancer Center, whose diagnosis fulfilled the criteria of IMC or DCIS with mucin production.
  • When identified on core needle biopsy, the presence of vascularized mucin should not be used alone to discriminate between invasive and in situ carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / blood supply. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983463.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Mucins; 0 / Trans-Activators; 0 / Vascular Endothelial Growth Factor A; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


30. Simpson RH, Desai S, Di Palma S: Salivary duct carcinoma in situ of the parotid gland. Histopathology; 2008 Oct;53(4):416-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary duct carcinoma in situ of the parotid gland.
  • AIMS: To describe three cases of purely in situ salivary duct carcinoma, so as better to define the entity.
  • In two cases the androgen receptor (AR) reaction was strong, but there was no immunohistochemical expression of HER2 protein or gene amplification by in situ hybridization.
  • CONCLUSIONS: Salivary duct carcinoma in situ is morphologically similar to breast ductal carcinoma in situ and, although our cases are few, salivary duct carcinoma in situ can possibly be subdivided into luminal and non-luminal cell types, as can analogous mammary neoplasms.
  • The present study cannot determine whether low-grade cribriform cystadenocarcinoma, architecturally similar but immunohistochemically different, is part of the spectrum of salivary duct carcinoma in situ, or whether it represents a separate entity.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Parotid Gland / pathology. Parotid Neoplasms / metabolism. Parotid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism. Salivary Ducts / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983607.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


31. Tot T: The origins of early breast carcinoma. Semin Diagn Pathol; 2010 Feb;27(1):62-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origins of early breast carcinoma.
  • Assessing the distribution of the in situ and invasive components of breast carcinomas and the extent of the disease represent an integrated part of our diagnostic routine.
  • In this article, we summarize findings from 792 consecutive breast carcinoma cases, each documented in large-format histology slides.
  • Of these, 35.0% (42/120) of the purely in situ carcinomas were diffuse and occupied mostly larger ducts, whereas 37.5% (45/120) were multifocal and involved several distant terminal ductal-lobular units (TDLUs).
  • The proportion of unifocal in situ cases involving a single TDLU or several neighboring TDLUs was 27.5% (33/120).
  • Forty-one percent (136/332) of early (< 15 mm) invasive carcinomas and 40.0% (136/340) of larger invasive tumors contained only a single invasive focus, with or without an in situ component within it.
  • The remaining tumors were nonunifocal because of multiple invasive or multiple in situ foci or both.
  • The proportion of extensive nonunifocal cases within purely in situ, early invasive, and more advanced invasive cases were 45.0% (54/120), 42.5% (141/332), and 42.4% (144/340), respectively.
  • Breast carcinoma seems to develop within a field of genetic alterations, often at multiple sites, and a considerable proportion of the cases comprise extensive lesions occupying a tissue space > or = 40 mm in all tumor size categories.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Precancerous Conditions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306831.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Cell cycle control related proteins (p53, p21, and Rb) and transforming growth factor beta (TGFbeta) in benign and carcinomatous (in situ and infiltrating) human breast: implications in malignant transformations. Cancer Invest; 2006 Mar;24(2):119-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle control related proteins (p53, p21, and Rb) and transforming growth factor beta (TGFbeta) in benign and carcinomatous (in situ and infiltrating) human breast: implications in malignant transformations.
  • A comparative study of the products of the cell cycle control genes p53 (mutated form), p21, Rb (nonphosphorylated and phosphorylated form) and TGFbeta was performed by immunohistochemistry and Western blot, in benign breast disorders and breast cancer (in situ and infiltrating tumors).
  • For the five proteins studied, the relative numbers of positively stained cells were higher in in situ carcinoma than in benign breast diseases.
  • In infiltrating breast tumors, the relative numbers of positively stained cells were even higher than in in situ tumors except for the percentage of pRb immunostained cells, which decreased slightly in infiltrative tumors.
  • For the other four proteins, the percentages of positively stained cases were similar to those found in in situ tumors.
  • In the three groups of patients, TGFbeta immunoreaction appeared in the cytoplasm while immunoreactions to p53, p21, Rb, and pRb were found always in the nucleus except for p21 in in situ tumors, which showed cytoplasmic immunoreaction.
  • Present results suggest that accumulation of mutated p53, cytoplasmic p21, and pRb in breast gland epithelium might be a crucial point in the development of in situ adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Cell Cycle Proteins / biosynthesis. Cell Transformation, Neoplastic / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537179.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Retinoblastoma Protein; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


33. Sóñora C, Mazal D, Berois N, Buisine MP, Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP, Osinaga E: Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues. J Histochem Cytochem; 2006 Mar;54(3):289-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues.
  • A deregulation of several MUC genes (MUC1, MUC2, MUC3, MUC5AC, and MUC6) was previously demonstrated in breast carcinomas.
  • Considering that recently we found the "non-mammary" MUC5B mRNA in primary breast tumors (Berois et al. 2003), we undertook the present study to evaluate the expression profile of MUC5B protein product in breast tissues, using LUM5B-2 antisera raised against sequences within the non-glycosylated regions of this apomucin.
  • Expression of MUC5B by breast cancer cells was confirmed by immunocytochemistry, in situ hybridization, and Western blot on MCF-7 cancer cells.
  • Using an immunohistochemical procedure, MUC5B apomucin was detected in 34/42 (81%) primary breast tumors, in 13/14 (92.8%) samples of non-malignant breast diseases, in 8/19 (42.1%) samples of normal-appearing breast epithelia adjacent to cancer, and in 0/5 normal control breast samples.
  • The staining pattern of MUC5B was very different when comparing breast cancer cells (cytoplasmic) and non-malignant breast cells (predominantly apical and in the secretory material).
  • We analyzed MUC5B mRNA expression using RT-PCR in bone marrow aspirates from 22/42 patients with breast cancer to compare with MUC5B protein expression in the primary tumors.
  • Our results show, for the first time at the protein level, that MUC5B apomucin is upregulated in breast cancer.
  • Its characterization could provide new insights about the glycobiology of breast cancer cells.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Aged, 80 and over. Apoproteins / biosynthesis. Blotting, Western. Bone Marrow / metabolism. Breast Diseases / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Lobular / metabolism. Carcinoma, Papillary / metabolism. Cell Line, Tumor. Female. Humans. Immunohistochemistry. In Situ Hybridization. Mammary Glands, Human / metabolism. Middle Aged. Mucin-5B. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation


34. Brandt SM, Young GQ, Hoda SA: The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol; 2008 May;15(3):140-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions.
  • The histologic triad of tubular carcinoma (TC), columnar cell lesion (CCL), and lobular carcinoma in situ (LCIS) has been recognized, but has not yet been fully characterized.
  • The diagnosis of TC was confirmed in 86 of our cases, and relevant patient data were analyzed.
  • On the basis of our review of the literature and our own experience, until such time as the biologic explanation and clinical implication of this triad is further elucidated, we recommend that pathologists be aware of this triad and should proactively seek the other 2 lesions if any one of these elements of this triad is identified in any diagnostic breast tissue.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434766.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


35. Graham AD, Faratian D, Rae F, Thomas JS: Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology; 2008 Jun;52(7):847-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
  • AIMS: To compare tissue microarray (TMA) and whole-section (WS) techniques in the routine assessment of HER-2 status in invasive breast cancer by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • METHODS AND RESULTS: HER-2 status was assessed prospectively in 106 consecutive cases of excised high-grade and/or node-positive breast carcinoma using both WS- and TMA-based techniques.
  • CONCLUSIONS: TMA technology is a robust method of assessing HER-2 status in invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Immunohistochemistry. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / metabolism. Tissue Array Analysis / methods
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. DNA, Neoplasm / analysis. Female. Humans. Prospective Studies. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Biospecimen Research Database. Biospecimen Research Database .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2009 Jun;54(7):901 [19635107.001]
  • (PMID = 18494613.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


36. Huemer GM, Schrenk P, Moser F, Wagner E, Wayand W: Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg; 2007 Aug;120(2):390-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers.
  • BACKGROUND: Operative techniques for oncoplastic reconstruction combine oncologic extirpation of the tumor with immediate reconstruction of breast shape and symmetry.
  • These techniques are increasingly being used for breast-conservation therapy of centrally located breast carcinomas.
  • The goal of this study was to provide an overview of the various surgical options for oncoplastic treatment of central breast carcinomas.
  • METHODS: From September of 1998 through January of 2005, 31 women (median age, 61 years) were treated for 32 centrally located breast carcinomas by breast-conserving therapy.
  • There were 27 invasive tumors (median size, 13.5 mm), and five patients had ductal carcinoma in situ (median size, 39.6 mm).
  • Two patients required a secondary mastectomy because of ductal carcinoma in situ with positive surgical margins in the final histology.
  • In a median follow-up of 33.8 months, there were no local recurrences in the remaining breast or axilla, but two patients developed distant metastases.
  • CONCLUSIONS: Breast carcinoma of small size that occurs in a central location can be safely treated oncologically by breast conservation therapy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632339.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Djidja MC, Francese S, Loadman PM, Sutton CW, Scriven P, Claude E, Snel MF, Franck J, Salzet M, Clench MR: Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections. Proteomics; 2009 May;9(10):2750-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections.
  • MALDI-mass spectrometry imaging (MALDI-MSI) has been used here for direct visualisation and in situ characterisation of proteins in breast tumour tissue section samples.
  • Frozen MCF7 breast tumour xenograft and human formalin-fixed paraffin-embedded breast cancer tissue sections were used.
  • In situ protein identification was carried out directly from the tissue section by MALDI-MSI.
  • [MeSH-major] Adenocarcinoma / chemistry. Neoplasm Proteins / analysis. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Trypsin / metabolism
  • [MeSH-minor] Animals. Breast Neoplasms / chemistry. Cell Line, Tumor. Detergents. Disease Models, Animal. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Paraffin Embedding. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19405023.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Detergents; 0 / Neoplasm Proteins; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


38. Levine P, Simsir A, Cangiarella J: Management issues in breast lesions diagnosed by fine-needle aspiration and percutaneous core breast biopsy. Am J Clin Pathol; 2006 Jun;125 Suppl:S124-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management issues in breast lesions diagnosed by fine-needle aspiration and percutaneous core breast biopsy.
  • The use offine-needle aspiration biopsy or percutaneous core needle biopsy to diagnose breast lesions has increased during the past few decades.
  • Although the benefits of these procedures are well known, controversies remain about the management of certain categories of breast lesions detected by these methods.
  • This article discusses the management issues in categories of breast lesions, including papillary lesions, atypical lobular hyperplasia and lobular carcinoma in situ, and mucinous lesions diagnosed by the preoperative techniques of aspiration or core biopsy.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830962.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 139
  •  go-up   go-down


39. Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A: Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet; 2005 Jan;271(1):62-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
  • A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps.
  • [MeSH-major] Adenocarcinoma / chemically induced. Anticarcinogenic Agents / adverse effects. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Chemotherapy, Adjuvant. Dilatation and Curettage. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hysteroscopy. Mastectomy, Radical. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290168.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


40. Hajek RA, King DW, Hernández-Valero MA, Kaufman RH, Liang JC, Chilton JA, Edwards CL, Wharton JT, Jones LA: Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):318-24
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero.
  • Epidemiologic studies have associated estrogens with human neoplasms such as those in the endometrium, cervix, vagina, breast, and liver.
  • In order to determine whether this effect was associated with chromosomal changes in humans, the frequencies of trisomy of chromosomes 1, 7, 11, and 17 were evaluated by the fluorescence in situ hybridization (FISH) technique in cervicovaginal tissue from 19 DES-exposed and 19 control women.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adult. Biopsy, Needle. Case-Control Studies. Female. Humans. In Situ Hybridization, Fluorescence. Incidence. Probability. Reference Values. Risk Assessment. Sensitivity and Specificity. Tissue Culture Techniques. Uterine Cervical Neoplasms / chemically induced. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / chemically induced. Vaginal Neoplasms / epidemiology. Vaginal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445652.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 16672; United States / NIMHD NIH HHS / MD / P60 MD 00503; United States / NCI NIH HHS / CA / R01 CA 44591; United States / NCI NIH HHS / CA / R01 CA 69375A-05S4; United States / NICHD NIH HHS / HD / T32 HD 07324; United States / ODCDC CDC HHS / CC / U48 CCU 619515-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


41. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases.
  • Breast metastases from extra-mammary malignancies, especially those mimicking primary inflammatory breast carcinoma, are extremely rare.
  • We report here two cases of inflammatory breast metastases from gastric or ovarian cancer.
  • Both patients, who had prior advanced malignant disease, presented with unilateral breast redness and swelling with peau d'orange sign, resembling primary inflammatory breast cancer or acute mastitis.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • Since breast metastasis is a sign of poor prognosis of the primary malignant disease, the possibility of breast metastasis should be considered in appropriate patients to preclude unnecessary major surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


42. Persons DL, Tubbs RR, Cooley LD, Dewald GW, Dowling PK, Du E, Mascarello JT, Rao KW, Wilson KS, Wolff DJ, Habegger-Vance G: HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med; 2006 Mar;130(3):325-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists.
  • CONTEXT: Fluorescence in situ hybridization (FISH) is a common method used to determine HER-2 status in breast cancer.
  • DESIGN: During the past 5 years, unstained sections from 9 invasive breast carcinomas were used for HER-2 FISH proficiency testing, allowing for comparison of FISH results among a large number of laboratories.
  • Reproducibility of test results among laboratories was excellent for breast tumors with low copy number (no HER-2 amplification) and for breast tumors with high copy number (HER-2 amplification).
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Cytogenetic Analysis / standards. In Situ Hybridization / standards. Receptor, ErbB-2 / genetics. Societies, Medical

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519559.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


43. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe; 2010 May;31(3):208-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
  • Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction.
  • However, testing of Her2 status by immunohistochemistry (IHC) differs from breast cancer in core aspects: 1.
  • Evaluation of Her2 in situ hybridization (ISH) is similar to breast cancer with ratio values of > or =2.0 indicating Her2 gene amplification.
  • In contrast to breast cancer, up to one-third of gastric cancers show a heterogeneous Her2 status both at IHC and ISH levels which favors bright field ISH over FISH.
  • [MeSH-major] Breast Neoplasms / genetics. Receptor, ErbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gene Amplification. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Neoplasm Metastasis


44. Wheeler DT, Kurman RJ: The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int J Gynecol Pathol; 2005 Apr;24(2):125-30
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma.
  • Routinely stained slides were examined from 50 invasive endocervical adenocarcinomas (37 of usual type and 13 of minimal deviation type), 26 noninvasive lesions (14 cases of adenocarcinoma in situ, 7 cases of hyperplasia, 4 cases of tunnel clusters, 1 adenomyoma), and 20 normal cervices, including 7 with deep nabothian cysts.
  • In conclusion, close proximity of glands to thick-wall blood vessels (distance from the closest gland to a thick-wall vessel less than or equal to the thickness of the vessel wall) seems to be a useful feature in the diagnosis of invasive endocervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Cervix Uteri / blood supply. Neoplasm Invasiveness / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Lissoni P, Messina G, Rovelli F, Brivio F, Fumagalli L, Villa S, Bartolacelli E: HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer. In Vivo; 2009 Nov-Dec;23(6):987-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
  • BACKGROUND: Node involvement, negative estrogen receptor (ER) and HER2 expression are the main negative prognostic factors for breast cancer.
  • Prolactin (PRL) is involved in the control of breast cancer growth and differentiation.
  • Surgery-induced hyperprolactinemia seems to be a positive prognostic factor for operable breast cancer, whereas high PRL levels may predict a poor prognosis in women with metastatic breast cancer.
  • In this study, we evaluated the relation between HER2 expression and PRL blood concentrations in women with metastatic breast cancer women and those whit operable breast cancer patients prior to before and 7 days after surgery.
  • PATIENTS AND METHODS: The study included 50 women with breast cancer, 22 of whom had metastatic disease.
  • HER 2 expression and serum levels of PRL were evaluated by fluorescence in situ hybridization (FISH) method and immunoradiometric assay (IRMA) method, respectively.
  • CONCLUSION: These preliminary results show that metastatic cancer-related hyperprolactinemia and lack of surgery-induced hyperprolactinemia are statistically more frequent in HER2-positive patients, thus suggesting a link between PRL endogenous secretion and HER2 expression in breast cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Hyperprolactinemia / genetics. Mastectomy / psychology. Prolactin / blood. Receptor, ErbB-2 / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Female. Humans. Immunoradiometric Assay. In Situ Hybridization, Fluorescence. Postoperative Complications / blood. Postoperative Period. Receptors, Estrogen


46. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M: Integrated profiling of basal and luminal breast cancers. Cancer Res; 2007 Dec 15;67(24):11565-75
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated profiling of basal and luminal breast cancers.
  • Basal and luminal are two molecular subtypes of breast cancer with opposite histoclinical features.
  • We report a combined, high-resolution analysis of genome copy number and gene expression in primary basal and luminal breast cancers.
  • We show that gain of 10p is a new alteration in basal breast cancer and that a subregion of the 8p12 amplification is specific of luminal tumors.
  • Second, we analyzed both aCGH and gene expression profiles for 42 basal and 32 luminal breast cancers.
  • The results support the existence of specific oncogenic pathways in basal and luminal breast cancers, involving several potential oncogenes and tumor suppressor genes (TSG).
  • In luminal breast cancers, 33 potential oncogenes were identified in 1q21-23, 8p12-q21, 11q13, and 16p12-13 and 61 candidate TSG in 16q12-13, 16q22-24, and 17p13.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosomes, Human, Pair 8. Gene Expression Profiling
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Chromosome Mapping. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification


47. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR: Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol; 2009;9:55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.
  • BACKGROUND: This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma.
  • METHODS: Dual-color fluorescence in situ hybridization and immunostaining were performed in twenty gastric cancer samples of individuals from Northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Brazil. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Case-Control Studies. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity / genetics. Male. Middle Aged

  • Genetic Alliance. consumer health - Chromosome 17, Deletion.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):1-7 [19264226.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] Acta Biochim Pol. 2003;50(1):231-8 [12673364.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):127-32 [15350302.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Histochemistry. 1988;89(4):307-16 [3410743.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):491-7 [2364362.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1575-84 [8909247.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1997 Feb;64(1):22-9 [9119949.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):166-70 [9075790.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Am J Phys Anthropol. 1999 Jun;109(2):175-80 [10378456.001]
  • [Cites] J Int Med Res. 1999 Mar-Apr;27(2):85-9 [10446695.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):467-70 [15795596.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1759-66 [15827559.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6207-11 [17036397.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):38-43 [10958939.001]
  • [Cites] Clin Exp Med. 2006 Oct;6(3):129-33 [17061062.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Arq Gastroenterol. 2006 Jul-Sep;43(3):247-51 [17160244.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8 [18091326.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1501-8 [11045566.001]
  • (PMID = 19619279.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2716360
  •  go-up   go-down


48. Buxant F, Noël JC: Pl6 expression in Paget's disease of the breast. Eur J Gynaecol Oncol; 2008;29(5):441-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pl6 expression in Paget's disease of the breast.
  • BACKGROUND: Paget's disease of the nipple is generally associated with an underlying invasive cancer or an underlying ductal carcinoma in situ.
  • Epidermotropic theory maintains that Paget's cells are derived from an underlying mammary in situ adenocarcinoma.
  • Because p16 protein plays a major role in cell-cycle control and in tumoral cell mobility, we analyzed p16 expression in Paget's disease of the nipple and in associated underlying ductal carcinoma in situ.
  • METHODS: The expression of p16 protein was analyzed by immunohistochemistry in eight cases of Paget's disease of the nipple with associated underlying ductal carcinoma in situ.
  • RESULTS: The expression of p16 protein was observed in 87.5% (7/8 cases) both in the nipple disease and in the associated underlying ductal carcinoma in situ.
  • In normal breast tissue, no expression of the protein was observed.
  • CONCLUSION: The positive p16 expression in Paget's disease of the nipple and the underlined ductal carcinoma in situ and its role in cell motility lead us to propose a role of p16 in the spread of this disease.
  • [MeSH-minor] Carcinoma in Situ / chemistry. Carcinoma, Ductal / chemistry. Female. Humans. Immunohistochemistry. Nipples / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051808.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


49. Cupp JS, Wrede JE, Cherry AM, Arber DA, George TI: Chromosomal aberrations in a case of synchronous extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type and bronchogenic adenocarcinoma. Appl Immunohistochem Mol Morphol; 2008 May;16(3):296-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in a case of synchronous extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type and bronchogenic adenocarcinoma.
  • We present the chromosomal aberrations in a case of synchronous extranodal marginal zone B-cell lymphoma and bronchogenic adenocarcinoma with bronchioloalveolar features.
  • Using fluorescence in situ hybridization, we identified deletion of the immunoglobulin heavy chain gene in the lymphomatous component, but not the carcinomatous component.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301237.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


50. Tan PH, Tse GM, Bay BH: Mucinous breast lesions: diagnostic challenges. J Clin Pathol; 2008 Jan;61(1):11-9
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous breast lesions: diagnostic challenges.
  • Breast lesions with mucin represent a broad spectrum of entities, ranging from benign fibrocystic changes with luminal mucin to mucocele-like lesions (MLL), which can be associated with banal epithelial alterations, atypical ductal hyperplasia or ductal carcinoma in situ.
  • [MeSH-major] Breast Diseases / pathology. Breast Neoplasms / pathology. Mucins / analysis
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Breast / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / pathology. Mucocele / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873114.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 52
  •  go-up   go-down


51. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Selective Estrogen Receptor Modulators / adverse effects. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


52. Letessier A, Ginestier C, Charafe-Jauffret E, Cervera N, Adélaïde J, Gelsi-Boyer V, Ahomadegbe JC, Benard J, Jacquemier J, Birnbaum D, Chaffanet M: ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer; 2005 Sep;44(1):103-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ETV6 gene rearrangements in invasive breast carcinoma.
  • We looked for ETV6 rearrangements in invasive breast cancer using fluorescence in situ hybridization (FISH) of BAC probes on sections of tissue microarrays containing 632 tumor samples.
  • [MeSH-major] Breast Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Artificial Gene Fusion. Centromere / genetics. Chromosome Mapping. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-ets. Telomere / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15887243.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


53. Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW: HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol; 2006 Jul;126(1):55-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 amplification in tubular carcinoma of the breast.
  • The prognostic and therapeutic implications of HER-2 gene amplification and estrogen and progesterone receptor status in breast cancer are well described.
  • To address the relative paucity of information concerning HER-2 amplification for tubular carcinomas, we assessed the frequency of gene amplification in 55 tubular carcinomas of the breast from 54 patients, 5 of which had axillary node metastases.
  • The HER-2 gene copy number was assessed by fluorescence in situ hybridization for the majority of tumors analyzed, whereas estrogen and progesterone receptor status was achieved by immunohistochemical analysis.
  • HER-2 gene amplification likely occurs infrequently, or not at all, in tubular carcinomas of the breast, whereas most express estrogen receptors.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Gene Amplification. Genes, erbB-2. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Axilla. Biomarkers, Tumor / metabolism. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Lymphatic Metastasis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753605.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


54. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Matei M, Azoicăi D: [Histopathological characteristics of genital and breast cancer included in epidemiologic study cohort]. Rev Med Chir Soc Med Nat Iasi; 2009 Apr-Jun;113(2):540-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathological characteristics of genital and breast cancer included in epidemiologic study cohort].
  • The correct management of genitals and breast cancers and the improving of the preventional and therapeutical successes ratio involve the knowledge of the histopathological features of these nosological entities which have different origins, different risk factors, different simptomatology and also different prognosis.
  • AIM: The descriptive evaluation of the histopathological features of the genitals and breast cancers to women from North-Eastern region of Romania.
  • MATERIAL AND METHOD: We have been included in the study 96 women (age range 23-77 years, mean 54,49) diagnosed with breast cancer, ovarian cancer, endometrial cancer and cervical cancer at the hospital admission, residency in the Obstetrics and Gynecology Clinics within 23 months.
  • The following main parameters were assessed: histological types, stage at diagnosis, Pap test.
  • RESULTS: The following cases' repartition on diagnostic types was observed: breast cancer (44 cases), cervical cancer (24 cases), endometrial cancer (16 cases) and ovarian cancer (12 cases).
  • In our study, the most affected range of age was 40-69 years for breast cancer, 30-59 years for cervical cancer, over 6 years for endometrial cancer and 50-59 years for ovarian cancer.
  • For the cervical neoplasia, 40% of analyzed cases were in incipient stages (in situ to IB stage lessions).
  • More than 50% of breast cancer cases have been diagnosed in advances stages (IIB to IIIC stages).
  • For the endometrium carcinoma, 45% of cases have been identified in incipient stages (in situ to IC).
  • CONCLUSION: From a histopathological point of view, for cervical neoplasia, squamous carcinoma was the most frequent type (87%), for breast neoplasia--invasive ductal carcinoma (80%) and for ovary and endometrium malignant tumors--adenocarcinoma (69%, respectively 83%).
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Genital Neoplasms, Female / epidemiology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Cohort Studies. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology. Prognosis. Risk Factors. Romania / epidemiology. Uterine Neoplasms / epidemiology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495363.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


56. Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, Toi M, Funata N, Eishi Y: HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med Dent Sci; 2010 Jun;57(2):155-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma.
  • HER2 oncoprotein plays an essential role in breast cancer growth and differentiation.
  • In the present study, we investigated the subcellular localization of HER2 protein in 1053 primary breast cancer tissues.
  • None of the 34 specimens showed amplification of the HER2 protein by fluorescence in situ hybridization.
  • Although the result is preliminary, it warrants further study on the role of the cytoplasmic variant form of HER2 in breast cancer growth, particularly in the aspect of neuroendocrine differentiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neuroendocrine Cells / pathology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD56 / analysis. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / pathology. Cell Differentiation. Chromogranin A / analysis. Coloring Agents. Cytoplasm / chemistry. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21073134.001).
  • [ISSN] 1342-8810
  • [Journal-full-title] Journal of medical and dental sciences
  • [ISO-abbreviation] J. Med. Dent. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Chromogranin A; 0 / Coloring Agents; 0 / Synaptophysin; EC 2.7.10.1 / Receptor, ErbB-2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


57. Ding HY, Yang GZ: [Clinicopathological features of the mucocele-like lesions in the breast]. Zhonghua Bing Li Xue Za Zhi; 2008 Jan;37(1):31-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features of the mucocele-like lesions in the breast].
  • OBJECTIVE: To study the clinical and pathological features of mucocele-like lesions in the breast.
  • METHODS: Nine cases of mucocele-like lesions in the breast were reported for the morphological and immunohistochemical features, the differential diagnosis, and a literature review.
  • RESULTS: All nine cases were from female patients, aged 23 to 43 years (mean 34 years), clinically presented with palpable breast masses.
  • CONCLUSION: Mucocele-like lesions of the breast is a group of mostly benign disease, and the differential diagnosis should include mucinous carcinoma.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Hyperplasia / pathology. Mucocele / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / diagnosis. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Intestinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509982.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


58. Bendrik C, Dabrosin C: Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol; 2009 Jan 1;182(1):371-8
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo.
  • IL-8 or CXCL8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer.
  • Estrogen is crucial in breast carcinogenesis and tumor progression.
  • Whether sex steroids affect IL-8 secretion of normal breast tissue or breast cancer is not known.
  • We used microdialysis to sample IL-8 in normal human breast tissue in situ in pre- and postmenopausal women, preoperatively in breast cancers of women, and in experimental breast cancer in mice.
  • We found a significant positive correlation between IL-8 and estradiol in normal breast tissue and hormone-dependent breast cancer in vivo.
  • Ex vivo, estradiol exposure increased the IL-8 secretion of normal whole breast tissue in culture.
  • In experimental breast cancer, estradiol increased IL-8 whereas the anti-estrogen tamoxifen inhibited the secretion of IL-8 both in vitro and extracellularly in vivo in tumors of nude mice.
  • Our results strongly suggest that estradiol has a critical role in the regulation of IL-8 in normal human breast tissue and human breast cancer.
  • IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.
  • [MeSH-major] Adenocarcinoma / secretion. Breast / immunology. Breast / secretion. Breast Neoplasms / secretion. Estradiol / physiology. Interleukin-8 / secretion. Up-Regulation / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109168.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 4TI98Z838E / Estradiol
  •  go-up   go-down


59. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol; 2007 Mar;31(3):417-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
  • This study was undertaken to determine the morphologic features and frequency of putative precursor lesions involved in the development of some pure forms of special types and low grade breast carcinoma.
  • The presence of preinvasive lesions including columnar cell lesions (CCLs), usual epithelial hyperplasia, ductal carcinoma in situ (DCIS), and lobular neoplasia (LN) was determined.
  • Our observations suggest that these lesions represent family members of low grade precursor, in situ and invasive neoplastic lesions of the breast.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Epithelial Cells / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):7-21 [23959112.001]
  • (PMID = 17325484.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Receptors, Estrogen
  •  go-up   go-down


60. Uzan C, Andre F, Scott V, Laurent I, Azria E, Suciu V, Balleyguier C, Lacroix L, Delaloge S, Vielh P: Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer. Cancer; 2009 Feb 25;117(1):32-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
  • METHODS: Ultrasound- or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions.
  • For malignant lesions, the authors attempted to correlate estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) on the surgical specimen.
  • The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion.
  • CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Breast Neoplasms / diagnosis. RNA, Messenger / isolation & purification
  • [MeSH-minor] Estrogen Receptor alpha / biosynthesis. Estrogen Receptor alpha / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19347827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


61. Strumylaite L, Bogusevicius A, Ryselis S, Pranys D, Poskiene L, Kregzdyte R, Abdrachmanovas O, Asadauskaite R: [Association between cadmium and breast cancer]. Medicina (Kaunas); 2008;44(6):415-20
Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between cadmium and breast cancer].
  • Cadmium is a known human lung carcinogen, although some studies indicate a link between cadmium exposure and human breast cancer.
  • The objective of this study was to assess cadmium concentration in breast tissue samples of patients with breast cancer and benign breast tumor.
  • The concentration of cadmium was determined in breast tissue samples of 21 breast cancer and 19 benign tumor patients.
  • Two samples of breast tissue from each patient, i.e. tumor and normal tissue close to tumor, were taken for the analysis.
  • RESULTS. In patients with breast cancer, the mean cadmium concentration was 33.1 ng/g (95% CI, 21.9-44.4) in malignant breast tissue and 10.4 ng/g (95% CI, 5.6-15.2) in normal breast tissue (P=0.002).
  • There was a statistically significant difference in cadmium concentration between malignant and benign breast tissues (P=0.009).
  • CONCLUSION. The data obtained show that cadmium concentration is significantly higher in malignant breast tissue as compared with normal breast tissue of the same women or benign breast tissue.
  • Further studies are necessary to determine the association between cadmium concentration in malignant breast tissue and estrogen receptor level, and smoking.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Breast / chemistry. Breast Neoplasms / chemistry. Cadmium / analysis. Carcinoma in Situ / chemistry. Carcinoma, Ductal, Breast / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660635.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 00BH33GNGH / Cadmium
  •  go-up   go-down


62. Artufel MV, Valero AC, Lladó RR, Sagalés NE, Llorca MC, Carazo AM, Cardó CC, Torrus XP: [Molecular protocol for HER2/neu analysis in breast carcinoma]. Clin Transl Oncol; 2005 Dec;7(11):504-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular protocol for HER2/neu analysis in breast carcinoma].
  • BACKGROUND: The HER2/neu proto-oncogene is frequently over-expressed in breast cancer and serves as a biological target for trastuzumab therapy.
  • METHODS: The present study was conducted to address this critical issue by prospectively analysing a large cohort of breast cancer patients (n = 222) and using a variety of methods.
  • To assess HER2/neu gene amplification, fluorescent in situ hybridisation (FISH) assays with gene-specific probes were conducted.
  • All procedures were applied to de-paraffinised tissue sections of breast tumour samples.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Genes, erbB-2. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Neoplasm Proteins / analysis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adult. Aged. Aged, 80 and over. Algorithms. Antibodies, Monoclonal / immunology. Breast Neoplasms, Male / chemistry. Breast Neoplasms, Male / genetics. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / genetics. False Positive Reactions. Female. Gene Amplification. Humans. Male. Middle Aged. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373062.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


63. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP: c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol; 2006 Apr;59(4):424-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-myc amplifications in primary breast carcinomas and their local recurrences.
  • OBJECTIVE: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas.
  • METHODS: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation.
  • CONCLUSIONS: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / genetics. Gene Amplification. Genes, myc. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Female. Genes, p53. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Middle Aged. Proportional Hazards Models. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1819-33 [11865060.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1479-85 [14562020.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):252-63 [14716758.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):499-507 [14760071.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):185-90 [15057159.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Sep;41(1):1-11 [15236312.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):495-501 [1887859.001]
  • [Cites] Hum Mol Genet. 1992 Nov;1(8):625-32 [1301171.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(4):319-26 [8389501.001]
  • [Cites] Methods Enzymol. 1995;254:334-59 [8531697.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):267-72 [9258662.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1787-95 [9362445.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2755-66 [9652742.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):646-53 [9713268.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):437-46 [10023713.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):229-35 [15720997.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2813-20 [12115367.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4140-5 [10632352.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1065-71 [10713691.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):403-10 [11008201.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5922-8 [11085504.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1537-44 [11506963.001]
  • [Cites] Lab Invest. 2001 Nov;81(11):1545-51 [11706062.001]
  • [Cites] Int J Mol Med. 2002 Feb;9(2):189-96 [11786932.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] J Pathol. 2002 Oct;198(2):190-7 [12237878.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):910-9 [12569590.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1186-95 [12654426.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1093-102 [12945077.001]
  • [Cites] J Pathol. 2003 Sep;201(1):75-82 [12950019.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):35-42 [11948489.001]
  • (PMID = 16497871.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC1860364
  •  go-up   go-down


64. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res; 2006 Jan 1;12(1):57-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
  • PURPOSE: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers.
  • EXPERIMENTAL DESIGN: Here, we did a mutational analysis of the ERBB2 kinase domain by PCR single-strand conformational polymorphism assay in gastric, colorectal, and breast carcinoma tissues.
  • RESULTS: We detected the ERBB2 kinase domain mutations in 9 of 180 gastric carcinomas (5.0%), in 3 of 104 colorectal carcinomas (2.9%), and in 4 of 94 breast carcinomas (4.3%).
  • CONCLUSION: This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Colorectal Neoplasms / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. DNA Mutational Analysis. Female. Genes, ras / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Phosphatidylinositol 3-Kinases / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics


66. Trop I, David J, Lalonde L: Breast cancer staging: the role of the radiologist. Can Assoc Radiol J; 2005 Dec;56(5):324-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer staging: the role of the radiologist.
  • The role of the breast radiologist has evolved over the past years, with an increasing involvement in patient care.
  • This article reviews the elements of investigation that are important to the surgeon and oncologist in optimizing care for the newly diagnosed breast cancer patient, with the 6th edition of the TNM classification of the American Joint Committee on Cancer used as a reference.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Lymph Nodes / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Breast Diseases / pathology. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Mammography. Middle Aged. Nipples / pathology. Prognosis. Risk Factors. Sensitivity and Specificity. Sentinel Lymph Node Biopsy. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579027.001).
  • [ISSN] 0846-5371
  • [Journal-full-title] Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  • [ISO-abbreviation] Can Assoc Radiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 15
  •  go-up   go-down


67. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat; 2010 Dec;124(3):677-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
  • However, its role in the tumor progression of breast cancer has not been explored.
  • HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC).
  • While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01).
  • Significant differences of expression were also identified among the subgroups of BC examined: in decreasing order from invasive micropapillary carcinoma, ductal carcinoma, lobular carcinoma, papillary carcinoma, medullary carcinoma, to mucinous adenocarcinoma (P = 0.001), corresponding to their known clinical aggressiveness.
  • Further evaluation of this new marker in breast cancer is indicated.
  • [MeSH-major] Antigens, CD147 / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / immunology. Carcinoma / immunology. Carcinoma, Intraductal, Noninfiltrating / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. China. Disease-Free Survival. Female. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Time Factors. Treatment Outcome. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213083.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


68. Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J: CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Neoplasma; 2010;57(4):325-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
  • Breast cancer associated with BRCA1 and BRCA2 gene mutations differs from non-BRCA tumors in several respects.
  • Of 40 breast cancer samples examined, 15 and 9 were from BRCA1 and BRCA2 mutation carriers, respectively, and 16 from patients without mutation.
  • Fluorescence in situ hybridization showed that eight tumors exhibited CCND1 amplification (20%; 3 BRCA1, 3 BRCA2, 2 non-BRCA).
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Cyclin D1 / genetics. Gene Amplification. Germ-Line Mutation / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Apoptosis Regulatory Proteins. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Genetic Predisposition to Disease. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Young Adult


69. Cendán JC, Coco D, Copeland EM 3rd: Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins. J Am Coll Surg; 2005 Aug;201(2):194-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins.
  • BACKGROUND: My colleagues and I have been using intraoperative frozen-section analysis (FSA) to evaluate lumpectomy margins in an attempt to reduce the number of additional operations that patients with ductal carcinoma in situ or stage I and II breast cancer would have to endure.
  • We review our experience in breast-conservation therapy (BCT) at the University of Florida (Gainesville) to determine the effectiveness of this approach.
  • False negatives were identified in 22 patients, affecting the operative pathway of 19 patients (19.6%) and were identified more frequently in cases of ductal carcinoma in situ (p < 0.001).
  • Ductal carcinoma in situ is more difficult to identify in FSA.
  • [MeSH-major] Breast Neoplasms / pathology. Frozen Sections / methods. Intraoperative Care / methods. Mastectomy, Segmental
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Algorithms. Biopsy, Needle / methods. Biopsy, Needle / standards. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Chi-Square Distribution. Decision Trees. False Negative Reactions. Female. Florida. Hospitals, University. Humans. Lymph Node Excision. Middle Aged. Retrospective Studies. Risk Factors. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038815.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Alex G: Apocrine adenocarcinoma of the nipple: a case report. Cases J; 2008;1(1):88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenocarcinoma of the nipple: a case report.
  • Apocrine carcinoma of the nipple is extremely rare and this case to the author's knowledge is only the third reported case worldwide and the first with associated ductal carcinoma in situ elsewhere in the breast.
  • A seventy one year old caucasian female presented to the breast clinic with a growth on her nipple which proved on histopathological analysis to be an apocrine carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Online J. 2008;14(6):5 [18713586.001]
  • [Cites] Acta Chir Belg. 2004 Aug;104(4):476-8 [15469170.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] J Neurooncol. 2006 May;77(3):285-9 [16314948.001]
  • (PMID = 18700029.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2526981
  •  go-up   go-down


71. Colleau M, Magalon G, Bonnier P: [Breast carcinoma diagnosed from surgical specimens. Retrospective study on three years]. Ann Chir Plast Esthet; 2005 Apr;50(2):127-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast carcinoma diagnosed from surgical specimens. Retrospective study on three years].
  • In the wake of three consecutive cases of microscopical examination of resection specimens following breast reduction revealing an adenocarcinoma, we wanted to point out the interest of a complete preoperative senological examination including mammography and postoperative anatomopathological examination.
  • We found seven patients (0.83%) with malignant breast cancer diagnosed on anatomopathological examination, which is comparable to the incidence found in literature.
  • Of these seven cases there were four ductal adenocarcinomas (0.47%), all of them in situ (DCIS), and three lobular adenocarcinomas (0.36%) of which one invasive (ILA), one in situ (LCIS) and one mixed.
  • In our opinion this shows that breast reduction can help in tracking down breast cancer and underlines the need for systematic and meticulous microscopic examination of resection specimens after breast reduction.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820598.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Rossi E, Villanacci V, Bassotti G, Casa DD, Missale G, Minelli L, Cestari R: Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol; 2006 Sep;15(3):125-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
  • Her-2/neu is a protooncogene frequently overexpressed in breast cancer, recently found to be also overexpressed in carcinoma arising on Barrett esophagus (BE).
  • Immunohistochemistry and fluorescence in situ hybridization (FISH) are conventionally used for Her-2 testing in carcinomas, but a single assay is not yet accepted as a "gold standard" in BE.
  • To evaluate the correlation between histopathology variables and gene expression/amplification in the sequence BE-low grade dysplasia-high grade dysplasia-adenocarcinoma, fifty esophageal specimens from patients with a diagnosis of BE (21 BE, 4 low-grade dysplasia, 12 high-grade dysplasia, and 13 adenocarcinomas) were evaluated.
  • [MeSH-major] Barrett Esophagus / diagnosis. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Aged. Female. Gene Amplification. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932066.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


73. Otsuki Y, Yamada M, Shimizu S, Suwa K, Yoshida M, Tanioka F, Ogawa H, Nasuno H, Serizawa A, Kobayashi H: Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int; 2007 Jul;57(7):421-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
  • The purpose of the present paper was to evaluate the clinicopathological and biological features of 20 Japanese patients with solid-papillary carcinoma of the breast (SPC) or SPC associated with invasive breast cancer.
  • The incidence of SPC among all the breast cancers treated at two institutions was 1.1% and 1.7%, respectively.
  • When all the cases were classified and analyzed according to both the 2002 tumor node metastasis (TNM) classification system and the Nottingham histological grade, SPC patients, even those with invasive cancers, seemed to have longer disease-free survival compared to patients with the other invasive breast cancers of matching grade and stage.
  • Clinicopathologically, SPC could be regarded as a separate type of ductal carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / chemistry. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587241.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


74. Goodman MT, Tung KH, Wilkens LR: Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000. Cancer Causes Control; 2006 Mar;17(2):127-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000.
  • OBJECTIVE: Few investigations of breast cancer among men have been conducted because of the relative rarity of this malignancy.
  • The objective of this analysis was to compare the demographic, pathological, and clinical features of breast cancer among men and women.
  • METHODS: Breast cancer among 6379 men and 744,275 women was identified through 34 US population-based registries in the US during the period 1996 to 2000.
  • RESULTS: The AAIR of breast cancer among men (16.6) was substantially lower than the incidence among women (1557.7).
  • Rates of breast cancer among black men were higher than among white and Asian-Pacific Island men, in contrast to women among whom rates in whites exceeded those among other ethnic groups.
  • Similar to women, breast cancer rates among non-Hispanic men were 50% greater than among Hispanic men.
  • Lobular breast cancers were less common among black men and women than among other ethnic groups.
  • In situ breast cancer was diagnosed in 10.8% of men and 16.2% of women.
  • Localized breast cancer was the most common stage at diagnosis in both sexes and all ethnic groups, although women were more likely than men to be diagnosed at a localized stage.
  • Cancer was 10% more likely to be diagnosed in the left breast than the right breast among men compared to 4% in women.
  • CONCLUSIONS: In spite of the rare incidence of breast cancer in men, the descriptive epidemiology of this malignancy is surprisingly similar to that in women.
  • An explanation for the greater relative incidence of breast cancer in black men is a research challenge.
  • [MeSH-major] Adenocarcinoma / epidemiology. Breast Neoplasms / epidemiology. Registries
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / ethnology. Child. Female. Humans. Incidence. Male. Middle Aged. Sex Distribution. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425090.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67001; United States / PHS HHS / / U75/CCU515998
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol; 2007 Jan;20(1):120-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
  • HER-2 is the target for antibody based treatment of breast cancer (Herceptin).
  • DAKO) and fluorescence in situ hybridization (FISH; PathVysion; Vysis-Abbott) for HER-2 amplification and overexpression.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Gene Amplification. Gene Expression Regulation, Neoplastic. Genes, erbB-2. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Matched-Pair Analysis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Time Factors. Tissue Array Analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143264.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


76. van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J: Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol; 2009 Jul;22(7):879-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
  • HER2 overexpression in breast cancer is associated with worse clinical outcome.
  • Therefore, 283 breast adenocarcinomas were included in a tissue microarray.
  • Immunohistochemistry using the 4B5 and CB11 antibodies, and fluorescence and chromogenic in situ hybridization (FISH or CISH) were performed.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies, Monoclonal / immunology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Menopause. Mice. Middle Aged. Observer Variation. Predictive Value of Tests. Rabbits. Reproducibility of Results. Tissue Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19305385.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


77. Thorne LB, Ryan JL, Elmore SH, Glaser SL, Gulley ML: Real-time PCR measures Epstein-Barr Virus DNA in archival breast adenocarcinomas. Diagn Mol Pathol; 2005 Mar;14(1):29-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time PCR measures Epstein-Barr Virus DNA in archival breast adenocarcinomas.
  • The role of Epstein-Barr Virus (EBV) in breast cancer pathogenesis remains controversial.
  • Fifty-five cases of paraffin-embedded, formalin-fixed invasive breast cancer were screened for the presence of EBV using quantitative polymerase chain reaction (PCR) directed at five different targets within the EBV genome (BamH1W, LMP1, EBNA1, LMP2, and BZLF1 regions).
  • Immunohistochemisty for viral BMRF1 and BZLF1 and in situ hybridization for lytic gene transcripts showed no evidence of replicative EBV gene expression.
  • Lymphocytes and malignant cells were also negative for latent infection by EBER in situ hybridization.
  • In conclusion, EBV DNA is detectable in a fraction of breast cancer specimens using real-time PCR as a screening tool, albeit at quite low levels, which suggests that only rare cells are infected.
  • [MeSH-major] Adenocarcinoma / virology. Breast Neoplasms / virology. DNA, Viral / genetics. DNA, Viral / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714061.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


78. de Candia P, Akram M, Benezra R, Brogi E: Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Hum Pathol; 2006 Aug;37(8):1032-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
  • We assessed the expression of Id4 messenger RNA (mRNA) in invasive mammary carcinoma from 31 patients, as well as in 21 cases of ductal carcinoma in situ, in 9 lymph node metastases, and in the morphologically normal epithelium adjacent to the carcinoma from the same subjects.
  • In addition, we evaluated Id4 mRNA in atypical ductal hyperplasia from 5 other women and in normal breast tissue from yet another 5 women with no history of breast malignancy or atypia.
  • Id4 mRNA was present in the normal ER-negative mammary epithelium in all cases; in contrast, the ER-positive cells present in the normal breast were Id4 negative.
  • Id4 mRNA was not detected in atypical ductal hyperplasia, in 22 of the 23 cases of ductal carcinoma in situ, and in 27 of the 31 invasive carcinomas (P = .0008), all of which were ER positive.
  • Our data show that Id4 is constitutively expressed in the normal human mammary epithelium but is suppressed in ER-positive breast carcinomas and preneoplastic lesions.
  • These results support a possible role of Id4 as a tumor suppressor factor in the human breast and suggest that the expression of Id4 in the mammary ductal epithelium may be regulated by estrogen.
  • Further investigations are required to define the functions of Id4 in the human normal breast and in mammary neoplasia.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Helix-Loop-Helix Motifs. Inhibitor of Differentiation Proteins / genetics. RNA, Messenger / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / cytology. Breast / metabolism. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Middle Aged. Neoplasm Staging. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867866.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


79. Louie LD, Crowe JP, Dawson AE, Lee KB, Baynes DL, Dowdy T, Kim JA: Identification of breast cancer in patients with pathologic nipple discharge: does ductoscopy predict malignancy? Am J Surg; 2006 Oct;192(4):530-3
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of breast cancer in patients with pathologic nipple discharge: does ductoscopy predict malignancy?
  • OBJECTIVE: The purpose of the current study was to review characteristics of patients with nipple discharge who underwent ductoscopy-assisted excisional biopsy who had a final diagnosis of carcinoma.
  • METHODS: A retrospective review was performed of patients presenting with pathologic nipple discharge (PND) who underwent ductoscopy-assisted excisional biopsy and had a final diagnosis of carcinoma.
  • RESULTS: A total of 14 (7%) of 188 patients who underwent ductoscopy-assisted excision had a final pathology of ductal carcinoma-in-situ (DCIS) (12/14, 86%) or invasive breast cancer with DCIS (2/14, 14%).
  • Duct wall irregularities or intraluminal growths were visualized during ductoscopy in 8 of the 14 (57%) breast cancer patients.
  • There were no visual abnormalities noted during ductoscopy that accurately predicted a final diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Endoscopy. Exudates and Transudates / secretion. Mammary Glands, Human / pathology. Nipples / secretion

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978968.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Kammori M, Izumiyama N, Hashimoto M, Nakamura K, Okano T, Kurabayashi R, Naoki H, Honma N, Ogawa T, Kaminishi M, Takubo K: Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy. Int J Oncol; 2005 Nov;27(5):1257-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy.
  • In situ detection of hTERT will aid in determining the localization of telomerase-positive cells.
  • The aim of this study was to detect expression of hTERT mRNA, hTERT protein, estrogen receptor (ER) and progesterone receptor (PR) in paraffin-embedded breast tissue samples and to investigate the relationship between hTERT expression and various clinicopathological parameters in breast tumorigenesis.
  • We used in situ hybridization (ISH) to examine hTERT gene expression, and immunohistochemistry (IHC) to examine expression of hTERT protein, ER and PR, in breast tissues including 64 adenocarcinomas, 2 phyllode tumors and their adjacent normal breast tissues. hTERT gene expression was detected by ISH in 56 (88%) carcinomas, but in neither of the 2 phyllode tumors. hTERT protein expression was detected by IHC in 52 (81%) carcinomas, but in neither of the 2 phyllode tumors.
  • In 4 cases of breast carcinoma that strongly expressed hTERT gene and protein before treatment, neo-adjuvant chemotherapy led to disappearance of gene and protein expression in all cases.
  • There was a strong correlation between detection of hTERT gene expression by ISH and of hTERT protein by ICH in tissue specimens from breast tumors.
  • These results suggest that detection of hTERT protein by ICH can be used to distinguish breast cancers as a potential diagnostic and therapeutic marker.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Telomerase / biosynthesis. Telomerase / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Gene Expression Profiling. Humans. In Situ Hybridization. Middle Aged. Neoadjuvant Therapy. Phyllodes Tumor. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211220.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


81. Wei B, Bu H, Chen HJ, Zhang HY, Li XJ: [Clinicopathologic study of solid papillary carcinoma of breast]. Zhonghua Bing Li Xue Za Zhi; 2006 Oct;35(10):589-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of solid papillary carcinoma of breast].
  • OBJECTIVE: To study the clinicopathologic features and immunophenotype of solid papillary carcinoma (SPC) of breast.
  • Seven cases contained foci of invasive carcinoma which showed similar cytologic features as those of the in-situ component.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Chromogranin A / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-8 / metabolism. Mastectomy / methods. Middle Aged. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134565.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Chromogranin A; 0 / Keratin-8; 0 / Synaptophysin
  •  go-up   go-down


82. Frenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, Leblanc A, Cohen L, Banerji P, Banerji P: Cytotoxic effects of ultra-diluted remedies on breast cancer cells. Int J Oncol; 2010 Feb;36(2):395-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effects of ultra-diluted remedies on breast cancer cells.
  • We conducted an in vitro study to determine if products prescribed by a clinic in India have any effect on breast cancer cell lines.
  • We studied four ultra-diluted remedies (Carcinosin, Phytolacca, Conium and Thuja) against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE).
  • The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Homeopathy / methods. Phytotherapy / methods
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Separation. Cell Survival / drug effects. Chromatography, High Pressure Liquid. Conium / chemistry. Female. Flow Cytometry. Gene Expression / drug effects. Humans. In Situ Hybridization, Fluorescence. India. Phytolacca / chemistry. Telomere / drug effects. Thuja / chemistry


83. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • No p75NTR expression was found in the malignant cells in all in situ carcinomas, invasive lobular carcinomas (n = 11), tubular carcinomas (n = 10), invasive papillary carcinomas (n = 6), mucinous carcinomas (n = 4), and medullary carcinomas (n = 2).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


84. Barnes PJ, Boutilier R, Chiasson D, Rayson D: Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat; 2005 May;91(2):173-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
  • BACKGROUND: Metaplastic breast carcinomas (MBC) are rare primary breast malignancies characterized by the co-existence of carcinoma with non-epithelial cellular elements.
  • They can be classified as monophasic spindle cell (sarcomatoid) carcinoma, biphasic carcinosarcoma, adenocarcinoma with divergent stromal differentiation (osseous, chondroid and rarely rhabdoid) as well as adenosquamous and pure squamous cell carcinomas.
  • Associated ductal carcinoma in situ (DCIS) was present in 11 cases.
  • CONCLUSIONS: Although a rare breast cancer subtype, MBC is of considerable interest due to its pathological heterogeneity and differences in clinical behavior compared to typical breast carcinomas.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868445.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


85. Sung JS, Park KH, Kim YH: Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. Cancer Genet Cytogenet; 2010 Apr 1;198(1):27-34
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients.
  • To further validate the gain of chromosome 11p region that was identified by array CGH, fluorescence in situ hybridization (FISH) was performed.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 11. Comparative Genomic Hybridization / methods. DNA Copy Number Variations. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Genetic Markers. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303011.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


86. Tanaka K, Komoike Y, Egawa C, Motomura K, Koyama H, Nagumo S, Kataoka TR, Inaji H: Indeterminate calcification and clustered cystic lesions are strongly predictive of the presence of mucocele-like tumor of the breast: a report of six cases. Breast Cancer; 2009;16(1):77-82
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indeterminate calcification and clustered cystic lesions are strongly predictive of the presence of mucocele-like tumor of the breast: a report of six cases.
  • Mucocele-like tumor (MLT) of the breast is a mucinous disorder that is generally difficult to distinguish from mucinous carcinoma.
  • Moreover, MLT is often accompanied by atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS), and preoperative diagnosis is very confusing.
  • Ultimately, excisional biopsies were performed to obtain a correct diagnosis in all cases.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology. Calcinosis / pathology. Mucocele / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Biopsy, Fine-Needle. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478314.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol; 2008 Feb;129(2):263-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
  • Clinical laboratory testing for human epidermal growth factor receptor 2 (HER2) status in newly diagnosed breast cancer is critically important for therapeutic decision making.
  • Unlike most pathologic testing, which serves as an adjunct to establishing a diagnosis, the results of HER2 testing stand alone in determining which patients are likely to respond to trastuzumab, a monoclonal antibody against HER2.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Genes, erbB-2
  • [MeSH-minor] Algorithms. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Guidelines as Topic. Humans. Immunohistochemistry / standards. In Situ Hybridization, Fluorescence / standards. Laboratories / standards. Quality Control. Sensitivity and Specificity. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2009 Jun;131(6):897-8; author reply 898-900 [19461099.001]
  • (PMID = 18208807.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  • [Number-of-references] 62
  •  go-up   go-down


88. Fong M, Henson DE, Devesa SS, Anderson WF: Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. Breast Cancer Res Treat; 2006 May;97(1):57-65
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii.
  • BACKGROUND: Ethnic diversity is well-documented for female breast carcinoma incidence in the continental US but is not so well-established in the state of Hawaii.
  • METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) program, we analyzed n=323,607 in situ and invasive female breast cancer cases for major ethnic groups in the continental US and in Hawaii, diagnosed during the years 1992-2002.
  • CONCLUSION: We observed inter- and intra-ethnic differences for female breast carcinoma in the continental US and in the state of Hawaii.
  • For example, API women with breast carcinoma in the continental US included 96.03% Asians and 2.4% Pacific Islanders.
  • In contrast, API women with breast carcinoma in Hawaii included 76.52% Asians and 23.46% Pacific Islanders.
  • [MeSH-major] Breast Neoplasms / ethnology. Ethnic Groups
  • [MeSH-minor] Adenocarcinoma / ethnology. Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / ethnology. Adenocarcinoma, Mucinous / etiology. Adenocarcinoma, Mucinous / pathology. African Americans. Age Distribution. Aged. Aged, 80 and over. Asian Americans. Carcinoma, Ductal, Breast / ethnology. Carcinoma, Ductal, Breast / etiology. Carcinoma, Ductal, Breast / pathology. Cohort Studies. European Continental Ancestry Group. Female. Hawaii / epidemiology. Humans. Incidence. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Ductal, Lobular, and Medullary / ethnology. Neoplasms, Ductal, Lobular, and Medullary / etiology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Odds Ratio. Pacific Islands. Population Surveillance. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk Factors. SEER Program. Survival Rate. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322891.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


89. Dubois V, Delort L, Mishellany F, Jarde T, Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP, Caldefie-Chezet F: Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res; 2010 Jul;30(7):2919-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?
  • BACKGROUND/AIM: Obesity increases the risk of breast cancer.
  • We have shown that two major adipokines, leptin and adiponectin, were expressed in mammary adenocarcinoma.
  • PATIENTS AND METHODS: Here, we evaluated zinc-alpha2-glycoprotein (ZAG) expression in tumor (n=55) and healthy (n=6) breast tissue by immunohistochemistry and examined whether it was correlated with that of major adipokines, usual tumor biomarkers (sex steroids receptors, i.e. estrogen (ER) and progesterone; Ki-67; cErb2), or apoptosis markers (Bcl2 and Bax).
  • CONCLUSION: These preliminary results suggest both a relationship between ZAG expression and pathways involving adipokines or estrogen and that ZAG may be a potential breast cancer biomarker.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Carrier Proteins / biosynthesis. Glycoproteins / biosynthesis
  • [MeSH-minor] Adiponectin / biosynthesis. Adult. Aged. Aged, 80 and over. Apoptosis / physiology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Case-Control Studies. Female. Humans. Immunohistochemistry. Leptin / biosynthesis. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. bcl-2-Associated X Protein / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683033.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / AZGP1 protein, human; 0 / Adiponectin; 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Leptin; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


90. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO: Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol; 2008 Apr;32(4):513-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
  • We have previously provided evidence showing an association between some precursor lesions with low nuclear grade breast carcinomas (LNGBCs).
  • Precursor lesions including columnar cell lesions, atypical ductal hyperplasia, ductal carcinoma in situ, usual epithelial hyperplasia, and lobular neoplasia were compared with matching "morphologically normal" terminal lobular duct units and matching invasive carcinoma.
  • The epithelial cells in the putative precursor flat epithelial atypia, atypical ductal hyperplasia, lobular neoplasia, ductal carcinoma in situ lesions, and their coexisting LNGBC were negative for basal and myoepithelial markers, but positive for CK19/18/8, estrogen receptor (ER)-alpha, Bcl-2, and cyclin D1.
  • The ER-alpha/ER-beta expression ratio increased during carcinogenesis, as did expression of cyclin D1 and Bcl-2. p53 immunopositivity was found 3% in LNGBC versus 43% in high nuclear grade breast carcinoma (HNGBC), whereas ataxia telangiectasia mutated expression was absent or reduced in 22% of LNGBC versus 53% of HNGBC cases.
  • These may represent a family of precursor, in situ and invasive neoplastic lesions belonging to the luminal "A" subclass of breast cancer.
  • Ataxia telangiectasia mutated may be one of the alternative regulatory mechanisms to TP53 mutation or dysfunction in low-grade and high-grade breast carcinoma.
  • [MeSH-major] Breast Neoplasms / chemistry. Breast Neoplasms / pathology. Mammary Glands, Human / chemistry. Mammary Glands, Human / pathology. Precancerous Conditions / chemistry. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Ataxia Telangiectasia Mutated Proteins. Carcinoma, Intraductal, Noninfiltrating / chemistry. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / pathology. Cell Cycle Proteins / analysis. Cyclin D. Cyclins / analysis. DNA-Binding Proteins / analysis. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Evolution, Molecular. Female. Humans. Hyperplasia. Immunohistochemistry. Keratin-18 / analysis. Keratin-19 / analysis. Keratin-8 / analysis. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin D; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / KRT18 protein, human; 0 / KRT8 protein, human; 0 / Keratin-18; 0 / Keratin-19; 0 / Keratin-8; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


91. Mecca P, Busam K: Primary male neuroendocrine adenocarcinoma involving the nipple simulating Merkel cell carcinoma - a diagnostic pitfall. J Cutan Pathol; 2008 Feb;35(2):207-11
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary male neuroendocrine adenocarcinoma involving the nipple simulating Merkel cell carcinoma - a diagnostic pitfall.
  • Male breast cancer is a rare entity accounting for < 1% of all breast cancer cases in the United States, but with a rate that has been rising over the last 25 years.
  • Likewise, true neuroendocrine carcinoma of the breast, defined as > 50% of tumor cells staining for either chromogranin or synaptophysin, is not a common entity, usually occurring in older women.
  • Myoepithelial cells within in situ areas were identified using stains for calponin and 4A4, supporting a primary mammary duct origin.
  • To the best of our knowledge, although reported in the male breast, no case of primary nipple neuroendocrine carcinoma in a male patient has been reported in the literature.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma, Merkel Cell / pathology. Carcinoma, Neuroendocrine / pathology. Diagnostic Errors. Nipples / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190447.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


92. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A: The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat; 2006 Feb;95(3):257-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
  • Here we explored the role of PPM1D aberrations in primary breast cancer.
  • On the other hand, these key cellular proteins are likely to be regulated through a complex fashion in breast cancer and apparently PPM1D represents only one of these mechanisms.
  • Taken together, our findings substantiate an important role for PPM1D in breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Amplification. Gene Expression Regulation, Enzymologic. Phosphoprotein Phosphatases / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction


93. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis; 2007 Jan;28(1):130-5
Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
  • Women at increased risk for breast cancer are often also at increased risk for ovarian cancer, reflecting common risk factors and intertwined etiologies for both diseases.
  • Unlike breast cancer prevention, primary ovarian cancer prevention has been impractical due to the low incidence, lack of risk and response biomarkers and difficulties in sampling ovarian tissue.
  • Challenges in the development of ovarian cancer prevention drugs, however, may be circumvented through the development of breast cancer prevention strategies that simultaneously decrease ovarian cancer.
  • All E2/DMBA-treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or invasive adenocarcinoma, while 50% also developed preneoplastic changes in the ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation).
  • This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Alkylating Agents / toxicity. Animals. Carcinogens / toxicity. Carcinoma, Intraductal, Noninfiltrating / chemically induced. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation / drug effects. Cells, Cultured. Cyclooxygenase 2 / metabolism. Disease Progression. Epithelium / drug effects. Estrogen Receptor alpha / metabolism. Estrogens / toxicity. Female. Hyperplasia / chemically induced. Hyperplasia / pathology. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Methylnitrosourea / toxicity. Precancerous Conditions. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891317.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA089019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Ki-67 Antigen; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 684-93-5 / Methylnitrosourea; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


94. Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH: The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol; 2007 Sep-Oct;8(5):390-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors.
  • OBJECTIVE: We wanted to evaluate the role of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) for detecting breast tumors, as compared with the T1- and T2-weighted images.
  • MATERIALS AND METHODS: Forty-one female patients underwent breast MRI, and this included the T1-, T2-, DWI and dynamic contrast-enhanced images.
  • Fifty-six breast lesions were detected on DWI and the histological diagnoses were as follows: 43 invasive ductal carcinomas, one mucinous carcinoma, one mixed infiltrative and mucinous carcinoma, seven ductal carcinomas in situ (DCIS), and four benign tumors.
  • First, we compared the detectability of breast lesions on DWI with that of the T1- and T2-weighted images.
  • We then compared the ADCs of the malignant and benign breast lesions to the ADCs of the normal fibroglandular tissue.
  • The detectabilities of breast lesions on the T1- and T2-weighted imaging were 61.5% (40/65) and 75.4% (49/65), respectively.
  • CONCLUSION: DWI has a high sensitivity for detecting breast tumors, and especially for detecting malignant breast tumors.
  • DWI was an effective imaging technique for detecting breast lesions, as compared to using the T1- and T2-weighted images.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Contrast Media / administration & dosage. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Imaging, Three-Dimensional / methods. Middle Aged. Observer Variation. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):975-83 [11105039.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Radiology. 2001 Jul;220(1):13-30 [11425968.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1403-9 [12034606.001]
  • [Cites] J Magn Reson Imaging. 2002 Jun;15(6):693-704 [12112520.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1042-6 [12488758.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):169-84 [12595101.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):654-61 [15390142.001]
  • [Cites] Stroke. 1997 Mar;28(3):481-2 [9056599.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):397-402 [9456953.001]
  • [Cites] Radiology. 1998 Sep;208(3):605-9 [9722835.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] JAMA. 2004 Dec 8;292(22):2735-42 [15585733.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):1014-9 [11105044.001]
  • (PMID = 17923781.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2626812
  •  go-up   go-down


95. Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM: HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci; 2008 Nov;53(11):3026-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.
  • HER2 gene amplification is an established predictive and prognostic marker in breast cancer.
  • We studied HER2 gene amplification, HER2 copy numbers, and chromosome 17 copy numbers using fluorescence in situ hybridization in 63 cases of resected pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Chromosomes, Human, Pair 17 / genetics. Gene Amplification / genetics. Gene Dosage / genetics. Genes, erbB-2 / genetics. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2009 Sep;54(9):2049-51 [19582575.001]
  • (PMID = 18463983.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Veronesi U, Luini A, Botteri E, Zurrida S, Monti S, Galimberti V, Cassano E, Latronico A, Pizzamiglio M, Viale G, Vezzoli D, Rotmensz N, Musmeci S, Bassi F, Burgoa L, Maisonneuve P, Paganelli G, Veronesi P: Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. Oncologist; 2010;15(12):1248-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases.
  • INTRODUCTION: In recent decades, a steady improvement in imaging diagnostics has been observed together with a rising adherence to regular clinical breast examinations.
  • All patients underwent radioguided occult lesion localization (ROLL), axillary dissection when appropriate, whole breast radiotherapy, or partial breast intraoperative irradiation and received tailored adjuvant systemic treatment.
  • Imaging showed a breast nodule in half of the cases and a breast nodule accompanied by microcalcifications in 9%.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Calcinosis / pathology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiography. Carcinoma in Situ / therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Intraductal, Noninfiltrating / therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Lobular / therapy. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Palpation. Prognosis. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Nucl Med. 2002 Jun;46(2):145-51 [12114878.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1839-40 [12453850.001]
  • [Cites] Lancet. 2003 Apr 26;361(9367):1405-10 [12727392.001]
  • [Cites] N Engl J Med. 1976 Jul 29;295(5):259-60 [934190.001]
  • [Cites] J Surg Oncol. 1978;10(3):251-71 [651373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1219-28 [20406961.001]
  • [Cites] Radiology. 1984 Mar;150(3):761-6 [6695077.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):522-5 [10215829.001]
  • [Cites] Lancet Oncol. 2006 Dec;7(12):983-90 [17138219.001]
  • [Cites] Eur J Cancer. 2009 May;45(8):1381-8 [19128957.001]
  • [Cites] J Med Screen. 2010;17(1):25-30 [20356942.001]
  • [Cites] Radiology. 1984 Feb;150(2):523-30 [6691113.001]
  • (PMID = 21147866.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227928
  •  go-up   go-down


97. Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M: Genome profiling of ERBB2-amplified breast cancers. BMC Cancer; 2010;10:539
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome profiling of ERBB2-amplified breast cancers.
  • BACKGROUND: Around 20% of breast cancers (BC) show ERBB2 gene amplification and overexpression of the ERBB2 tyrosine kinase receptor.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Gene Expression Profiling. Genome, Human. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Cohort Studies. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Phosphorylation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Nov 1;26(50):7163-9 [17525746.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):183-219 [18071947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jan 25;365(4):711-7 [18039470.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11565-75 [18089785.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):736-44 [18258981.001]
  • [Cites] Genome Biol. 2007;8(10):R215 [17925008.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):327-32 [18037662.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):333-41 [18174243.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1066-72 [18212337.001]
  • [Cites] Mol Cancer Res. 2008 Feb;6(2):212-21 [18314482.001]
  • [Cites] Carcinogenesis. 2008 Mar;29(3):473-9 [17916906.001]
  • [Cites] Lab Invest. 2008 May;88(5):491-503 [18332872.001]
  • [Cites] PLoS Genet. 2008 Apr;4(4):e1000054 [18437204.001]
  • [Cites] Growth Factors. 2004 Jun;22(2):89-95 [15253384.001]
  • [Cites] Nat Genet. 2008 May;40(5):623-30 [18372905.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3022-9 [18483367.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4201-9 [18519679.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):774-80 [18728668.001]
  • [Cites] BMC Cancer. 2008;8:288 [18840272.001]
  • [Cites] J Pathol. 2008 Dec;216(4):399-407 [18810758.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9982-6 [19047180.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):485-98 [19034632.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2970-2 [18816632.001]
  • [Cites] BMC Cancer. 2009;9:52 [19216735.001]
  • [Cites] Expert Rev Mol Med. 2009;11:e8 [19261198.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2711-22 [19318498.001]
  • [Cites] J Natl Cancer Inst. 2009 May 6;101(9):615-8 [19401550.001]
  • [Cites] Mod Pathol. 2010 Feb;23(2):270-5 [19946260.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(3):575-89 [19688261.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6315-21 [11607834.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1223-33 [12368196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] J Pathol. 2004 Mar;202(3):286-98 [14991893.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2564-75 [14743203.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):687-91 [1612775.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Aug;7(4):219-26 [7692948.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3576-80 [10446964.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11005-10 [16043716.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1126-34 [16161043.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1186-98 [16457699.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):39-49 [16601278.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):269-80 [16683005.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):761-9 [16708353.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):59-64 [16761619.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Growth Factors. 2006 Jun;24(2):121-36 [16801132.001]
  • [Cites] BMC Cancer. 2006;6:245 [17040570.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2919-30 [17121940.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):89-96 [17143483.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] OMICS. 2006 Winter;10(4):429-43 [17233555.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1959-70 [17001317.001]
  • [Cites] Breast Cancer. 2007;14(2):182-8 [17485904.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1520-5 [17426702.001]
  • [Cites] EMBO J. 2007 Jun 20;26(12):2843-55 [17525734.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5745-55 [17908964.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • (PMID = 20932292.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2958950
  •  go-up   go-down


98. Harvey JM, Sterrett GF, McEvoy S, Fritschi L, Jamrozik K, Ingram D, Joseph D, Dewar J, Byrne MJ, Key Cancers Patterns of Care Study Group: Pathology reporting of breast cancer: trends in 1989-1999, following the introduction of mammographic screening in Western Australia. Pathology; 2005 Oct;37(5):341-6
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology reporting of breast cancer: trends in 1989-1999, following the introduction of mammographic screening in Western Australia.
  • BACKGROUND: A survey of pathology reporting of breast cancer in Western Australia in 1989 highlighted the need for improvement.
  • The current study documents (1) changes in pathology reporting from 1989 to 1999 and (2) changes in patterns of histopathological prognostic indicators for breast cancer following introduction of mammographic screening in 1989.
  • METHODS: Data concerning all breast cancer cases reported in Western Australia in 1989, 1994 and 1999 were retrieved using the State Cancer Registry, Hospital Morbidity data system, and pathology laboratory records.
  • Pure ductal carcinoma in situ (DCIS) constituted 10.9% and 7.9% of total cases of breast carcinoma in 1999 and 1989, respectively (p = 0.01).
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Mammography. Medical Records / standards. Pathology, Surgical / standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pathology. 2005 Oct;37(5):339-40 [16194842.001]
  • (PMID = 16194843.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Gill PG, Luke CG, Roder DM: Clinical and pathological factors predictive of lymph node status in women with screen-detected breast cancer. Breast; 2006 Oct;15(5):640-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological factors predictive of lymph node status in women with screen-detected breast cancer.
  • Two thousand one hundred and thirty five asymptomatic invasive breast cancers detected through screening mammography were analysed to identify predictors of lymph node involvement.
  • Multivariable analysis indicated that predictors included larger tumour diameter, an infiltrating ductal or lobular histological type, multifocal disease, a palpable lesion, and a younger age at diagnosis.
  • An association also was found between nodal involvement and the presence of an extensive in situ component (EIC).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Models, Statistical
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adult. Aged. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Female. Humans. Logistic Models. Lymphatic Metastasis / diagnosis. Mammography / statistics & numerical data. Middle Aged. Neoplasm Staging. Predictive Value of Tests. South Australia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517164.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


100. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer; 2008;8:363
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
  • METHODS: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / genetics
  • [MeSH-minor] China. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 7. Female. Gene Dosage. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1162-7 [17487844.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):137-45 [11850542.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Leukemia. 2003 Mar;17(3):532-40 [12646941.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):233-9 [12925985.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):2087-90 [2564806.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):533-42 [8630962.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):448-53 [16297090.001]
  • [Cites] Science. 2006 Jun 23;312(5781):1798-802 [16794079.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):579-602 [17100565.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):414-22 [17473657.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:53-77 [11264450.001]
  • (PMID = 19061514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2613415
  •  go-up   go-down






Advertisement